More recently, RORγ has also been found to be the driver of the androgen receptor in metastatic castration resistant prostate cancer where the selective RORγ antagonist SR2211 elicits a potent cytostatic effect (Wang et al., 2016). This evidence concerns the gene RORC and prostate carcinoma.